Co-Authors
This is a "connection" page, showing publications co-authored by Franco Ruberto and Gabriella d'Ettorre.
Connection Strength
0.912
-
Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr. 2020; 7:613928.
Score: 0.231
-
Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020; 7:389.
Score: 0.223
-
Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. Intern Emerg Med. 2021 08; 16(5):1231-1237.
Score: 0.060
-
Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. Int J Cardiol. 2021 09 15; 339:235-242.
Score: 0.060
-
The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). J Med Virol. 2021 Jul; 93(7):4319-4325.
Score: 0.059
-
Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. J Med Virol. 2021 04; 93(4):2210-2220.
Score: 0.057
-
Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent. Eur J Clin Invest. 2021 Jan; 51(1):e13418.
Score: 0.057
-
Nox2 activation in Covid-19. Redox Biol. 2020 09; 36:101655.
Score: 0.056
-
Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circ Res. 2020 07 17; 127(3):400-401.
Score: 0.055
-
Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int J Antimicrob Agents. 2020 Aug; 56(2):106029.
Score: 0.055